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Colorectal cancer (CRC) is the third most common malignant disease in the United States (U.S.). 
Almost two-thirds of CRC survivors are living 5 years following diagnosis. The prevalence of 
CRC survivors is likely to increase dramatically over the coming decades with further advances in 
early detection and treatment and the aging and growth of the U.S. population. Survivors are at 
risk for a CRC recurrence, a new primary CRC, other cancers, as well as both short and long-term 
adverse effects of the CRC and the modalities used to treat it. CRC survivors may also have 
psychological, reproductive, genetic, social, and employment concerns following treatment. 
Communication and coordination of care between the treating oncologist and the primary care 
clinician is critical to effectively and efficiently manage the long-term care of CRC survivors. The 
following guidelines are intended to assist primary care clinicians in delivering risk-based health 
care for CRC survivors who have completed active therapy.
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INTRODUCTION
Over the past two decades, increasing attention has been given to understanding the long-
term and late effects experienced by cancer survivors as a result of their cancer diagnosis or 
treatment.1–4 Long-term (side) effects caused by cancer or its treatment that are present 
during treatment and may persist for months or years may be physical or psychosocial in 
nature. In contrast, late effects of the cancer or cancer therapy may occur months or even 
years after a cancer diagnosis and again may include second cancers, physical problems, or 
psychosocial issues. Along the cancer continuum, there are at least three distinct phases of 
cancer survivorship: from diagnosis to the end of initial treatment, the transition from 
treatment to extended survival, and long-term survival.5 While clinical practice guidelines 
exist for diagnosis and treatment, there are few evidence-based clinical care guidelines for 
posttreatment care. The ever increasing number of cancer survivors living posttreatment 
poses a challenge to oncology and primary care clinicians to provide ongoing optimal 
clinical follow-up care.6 To meet this demand, it is important to equip primary care 
clinicians with the necessary resources to recognize and manage the health risks and 
maximize quality of life (QoL) of cancer survivors. The National Comprehensive Cancer 
Network (NCCN) has developed consensus-based guidelines for treatment of patients with 
colon and rectal cancers, and which also include some recommendations regarding follow-
up care after completion of treatment.7,8 As well, the NCCN has developed survivorship 
care guidelines addressing long-term or late occurring psychosocial and physical problems 
and preventive health.9 In addition, the American Society of Clinical Oncology (ASCO) 
clinical practice guidelines for cancer survivorship care focus on prevention and 
management of symptoms experienced by survivors of many types of cancer. To date, ASCO 
has released three evidence-based cancer survivor care guidelines, focused on fatigue, 
anxiety and depression, and neuropathy.10–12 ASCO has also updated their fertility 
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preservation guideline13 and offers a provisional clinical opinion on the integration of 
palliative care into oncology care.14
This CRC survivorship care guideline builds on previous guidelines by providing primary 
care clinicians with recommendations for providing comprehensive care for CRC survivors. 
These guidelines provide guidance on 1) methods to identify and manage the potential 
physical and psychosocial long-term and late effects of CRC and its treatment; 2) 
surveillance for recurrence and screening for second primary cancers; 3) health promotion; 
and 4) how to enhance communication between the oncology team and primary care 
clinicians. The goal of these guidelines is to optimize the care delivered for cancer survivors, 
and to help improve the overall health and QoL of CRC survivors.
Gaps in posttreatment cancer survivorship resources and clinical follow-up care were 
identified through the work of the National Cancer Survivorship Resource Center (The 
Survivorship Center; cancer.org/survivorshipcenter).15 Aims of The Survivorship Center are 
to help survivors achieve optimal health and QoL and increase awareness of posttreatment 
survivorship as a public health issue. To this end, The Survivorship Center convened a group 
of experts to review existing literature and clinical practices to develop comprehensive 
clinical follow-up care guidelines for CRC survivors, specifically those who are stage I–III, 
with no evidence of disease.
BACKGROUND
Approximately 132,700 individuals will be diagnosed with CRC in the US in 2015.16 The 
incidence of CRC has declined over the past 20 years, in large part due to increased 
screening and removal of precancerous polyps. The rate of decline in incidence is greater 
among non-Hispanic white males than among African American males and similar between 
non-Hispanic white and African American females.16 Other racial and ethnic groups have 
lower incidence rates than these two populations.17 Approximately 49,700 patients will die 
from CRC in 2015.16 Mortality rates are highest among African American males and 
approximately 50% higher than the second highest group non-Hispanic white and American 
Indian / Alaska Native males. Among females, mortality rates are significantly higher for 
African Americans, followed by American Indians / Alaska Natives and non-Hispanic 
whites.17 (Figure 1: Colorectal Cancer Incidence and Mortality Rates* by Race/Ethnicity 
and Sex, United States, 2006–2010)18
Colorectal cancer survivors comprise about 9% of the nearly 15 million cancer survivors 
alive in the U.S., making it the second and third most common cancer site among male and 
female cancer survivors, respectively.19 The majority of CRC survivors are age 60 or 
older.16 The overall health and QoL experienced by survivors is, in part, influenced by the 
stage at diagnosis and the types and duration of therapy. Only 40% of CRC is diagnosed at a 
local stage (stages I & II), whereas 36% of cancers are diagnosed at a regional stage, 
involving the regional lymph nodes (stage III) and 20% are diagnosed at a distant stage 
when distant metastases have occurred (stage IV).17 The type of treatment will vary 
depending on the stage at diagnosis, but the most common treatment is surgery, with 
additional therapy including systemic chemotherapy and radiation therapy (the latter is 
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employed much more often in rectal cancer than in colon cancer) given either in the 
neoadjuvant or adjuvant setting. Potential physical long-term and late effects affecting CRC 
survivors include chronic peripheral neuropathy, infertility, secondary cancers, and bowel 
dysfunction. Survivors may also experience psychosocial issues such as distress, depression, 
anxiety, body image, sexual dysfunction and intimacy concerns, as well as financial issues 
resulting from workforce displacement and/or costs of treatment.20
METHODS
Literature Review
To develop the ACS CRC Survivorship Care Guidelines, The Survivorship Center staff 
conducted an initial review of relevant literature and reviewed publically available U.S. and 
international clinical practice guidelines. The original literature search was conducted in the 
fall of 2011 using PubMed, identifying articles published between 2000 and 2011 using 
combinations of the following key words and phrases: cancer survivor, colon cancer, rectal 
cancer, colorectal cancer, chemotherapy, cognitive dysfunction, depression, distress 
management, fecal incontinence, follow-up care, genetic counseling and testing, guidance, 
guidelines, hand and foot syndrome, health promotion, late effects, late sequelae, long-term 
effects, meta-analysis, monitoring, neuropathy, pain management, palliative care, post-
treatment, primary care physician, psychosocial, radiation, recurrence, screening, second 
cancer, sexual dysfunction, surgery, surveillance, survivor, survivorship, symptom 
management, systematic review, and treatment complications. Studies were excluded that a) 
reported on studies of childhood cancer, b) reported on qualitative studies, c) were published 
in languages other than English, and c) specifically addressed metastatic (stage IV) CRC 
(due to the likelihood that these survivors participate in ongoing treatment and do not fall 
into the “long-term / extended survivorship” phases).
In January and February 2012, the initial literature search was supplemented by an 
environmental scan of publically available U.S. and international clinical practice guidelines 
and reports relevant to the clinical management of CRC patients and survivors, regardless of 
intended readership. Surveillance guidelines specific to CRC from the National 
Comprehensive Cancer Network (NCCN) and national and international sources relevant to 
the impact of CRC and interventions for long-term and late effects were reviewed. Sources 
included: ACS, American College of Gastroenterology, American Gastroenterological 
Association, American Psychosocial Oncology Society, ASCO, American Society of Colon 
and Rectal Surgeons, American Society for Gastrointestinal Endoscopy, American Society 
for Radiation Oncology, Canadian Association of Psychosocial Oncology, Institute of 
Medicine, National Cancer Institute, NCCN, National Guidelines Clearinghouse, MD 
Anderson Clinical Tools and Resources Colon and Rectal Cancer Survivorship algorithm, 
Oncology Nursing Society, Society of American Gastrointestinal and Endoscopic Surgeons, 
Society of Gastroenterology Nurses and Associates, Inc., and the Society of Surgical 
Oncology.
From May 2012 through June 2014, the CRC guideline was put on hold as The Survivorship 
Center directed it efforts to writing the ACS Prostate Cancer Survivorship Care Guidelines 
manuscript.21 In September 2014, The Survivorship Center reconvened the CRC 
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Survivorship Care Guidelines expert workgroup to update the literature review, review the 
levels of evidence according to previously published methods, and consider any revisions. A 
small writing group was convened to complete the guidelines manuscript.
Due to the time lapse, in September 2014, an updated literature search was conducted. 
Search terms included cancer survivor + review or meta-analysis or systematic review + 
guidelines or guidance paired with colorectal cancer; colorectal cancer survivor or colorectal 
cancer patient post-treatment + (symptom management, late effects, long-term effects, 
psychosocial care, palliative care, health promotion, surveillance, screening for new cancers, 
self-management, guidelines or guidance, follow up or follow-up, side effects + 
chemotherapy, side effects + radiation, side effects + surgery, treatment complications, 
genetic counseling and testing, survivor or patient interventions, provider interventions, 
provider education, and barriers). Literature identified included: guidelines / guidance 
developed by other organizations (e.g. NCCN follow-up recommendations, ASCO follow-up 
recommendations), specific medical centers (e.g. MD Anderson), or available from other 
countries (e.g. Australian Cancer Survivorship Centre); recent meta-analyses and review 
papers (since 2004 following publication of the National Action Plan for Cancer 
Survivorship); and individual studies, with the highest priority given to papers that met the 
following criteria: peer reviewed publication in English since 2004, unless a seminal paper 
prior to this date still carries the most weight, including randomized controlled trials, 
prospective studies, and well-conducted population-based case-control studies; large studies 
of more than 200 cancer cases analyzed, and high quality assessment of covariates and 
analytic methods: analyses controlled for important confounders (e.g. pre-existing comorbid 
conditions).
A total of 226 articles (available as a literature review summary table supplement to this 
manuscript) met the inclusion criteria for the literature review and were used to create the 
guidelines.
Literature Synthesis and Workgroup Recommendations
In May 2012, The Survivorship Center staff integrated evidence from the initial literature 
review to develop an initial draft of CRC survivorship care guidelines that was reviewed by 
the expert workgroup. The Survivorship Center Steering Committee and staff, and ACS 
leadership nominated experts practicing in either primary care or surgical/oncological 
settings that care for CRC survivors. Workgroup members were selected based on their 
expertise in at least one of the following domains: gastroenterology, health services, medical 
oncology, oncology nursing, preventive medicine, primary care, public health, and surgical 
oncology. The expert workgroup consisted of 9 initial members who were emailed a 
structured 13-question survey about the accuracy and relevance of the draft guidelines 
document (Appendix A). Written responses were compiled and distributed in advance of a 
conference call to discuss the feedback and reach consensus on conflicting 
recommendations.
Led by Khaled El-Shami, MD, PhD, The GW Medical Faculty Associates, a Hematologist/
Oncologist with board certification in Medical Oncology and Internal Medicine, the 
workgroup participated in a webinar discussion of the existing evidence base as well as 
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themes and discrepancies from the comments. Based on written and verbal feedback, The 
Survivorship Center staff revised the draft guidelines. The Survivorship Center staff sought 
additional evidence and clinical expertise to support practice-based recommendations and 
explore issues identified by the expert workgroup members that were not identified by the 
literature review. Based on a combination of published evidence and practice-based 
experience, The Survivorship Center staff drafted clinical follow-up care recommendations 
to be considered for inclusion in the guidelines. This revised draft of guidelines 
recommendations was presented to the American Cancer Society Mission Outcomes 
Committee, Chief Medical Officer, and National Board of Directors for review and were 
approved in May 2012.
In September 2014, the initial literature review was updated using the search terms outlined 
in the previous section.21 Workgroup members were asked to consider the following criteria 
as they synthesized their findings from the published literature:
a. level of evidence: I – Meta analyses of randomized controlled trials (RCTs), IA – 
RCT of CRC survivors; IB – RCT based on cancer survivors across multiple 
sites, IC – RCT not based on cancer survivors, but on general population 
experiencing a specific long-term or late effect (e.g. managing urinary 
incontinence, erectile dysfunction, etc.); IIA – non-RCT based on CRC 
survivors, IIB – non-RCT based on cancer survivors across multiple sites, IIC – 
non-RCT not based on cancer survivors, but on general population experiencing 
a specific long-term or late effect; III – case study; 0 – expert opinion, 
observation, clinical practice, literature review, or pilot study.
b. consistency across studies, including across study designs (separating results by 
study design when presenting the evidence);
c. dose-response when presenting long-term or late effects associated with chemo- 
or radiation therapy;
d. race / ethnicity differences in diagnosis and treatment that may impact the risk of 
long-term or late effects; and
e. second primary cancers for which CRC survivors are at high risk due to cancer 
treatment exposure, genetic factors, lifestyle behaviors, etc.
While new articles were added to the literature review, there was no change in the 
guidelines. In May 2015, the guidelines manuscript was sent to internal and external experts 
for final review and comment prior to submission for publication. The process of guideline 
development was aligned with the ACS process for creating cancer screening guidelines, and 
a comparison of this methodology has been previously published.21 In December of 2011,22 
changes were put into effect to ensure the ACS process was in alignment with the new 
Institute of Medicine standards for how guidelines should be developed.23 According to the 
ACS process, every five years these guidelines will be updated as new research is available 
to support revision.
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GUIDELINES FOR THE PRIMARY CARE MANAGEMENT OF COLORECTAL 
CANCER SURVIVORS
Each of the essential components of comprehensive cancer survivorship care are discussed 
in the following sections: Surveillance for Colorectal Cancer Recurrence and Screening for 
Second Primary Cancers, Assessment and Management of Physical and Psychosocial 
Effects of Colorectal Cancer and Treatment, Routine Health Promotion Needs, and 
Coordination of Care Among Specialists and Primary Care Clinicians.1
SURVEILLANCE FOR COLORECTAL CANCER RECURRENCE
Surveillance for CRC recurrence is applicable to survivors who have completed primary 
treatment for stage I, II and III cancer and are without evidence of disease. The goal of 
surveillance is to detect recurrent or metachronous (e.g. new primary) disease early thereby 
improving long-term outcomes through timely intervention.
While these guidelines can be extrapolated to surveillance strategies for patients with stage I 
disease or patients with resected metastatic (stage IV) CRC without evidence of disease 
there are little to no data to inform these recommendations.
The ASCO clinical practice guideline endorsement of the Cancer Care Ontario Guidelines 
on Follow-up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors 
of Colorectal Cancer emphasized that if a patient is not a candidate for surgery or systemic 
therapy because of severe comorbid conditions, then surveillance tests should not be 
performed.24 Testing should only be performed in patients in whom the results will change 
treatment decisions. We endorse this ASCO recommendation.
Recommendation 1: Clinical follow-up care provided to CRC survivors should be 
individualized based on the specific diagnosis and treatment protocol. Level of Evidence = 
2A
The guiding principle of surveillance is that it should be based on assessment of a patient’s 
risk of recurrence, in the context of functional status and patient preferences. Factors 
associated with a high risk of recurrence include poorly differentiated histology (exclusive of 
those cancers that are microsatellite instability-high [MSI-H]), lymphatic or vascular 
invasion, bowel obstruction, having had fewer than 12 lymph nodes examined, perineural 
invasion, localized perforation, and close, indeterminate, or positive resection margins.
In addition, unless there is a family history or a known genetic syndrome, CRC survivors are 
at average risk for other cancers and it is recommended that primary care clinicians screen 
for second primary cancers, as they would in the general population.7,8
Recommendation 2: CRC survivors should receive surveillance colonoscopy according to 
a schedule based on based on risk. Level of Evidence = 2A
The survivorship timeline (time zero) starts at the time of resection (or time of diagnosis if 
resection is not part of index treatment). Testing intervals are based on the assumption that 
treatment is not ongoing and that no evidence of recurrence or metastatic disease was found 
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at the end of treatment. The literature is not definitive with regard to how often surveillance 
for recurrent disease should be conducted and, to a lesser extent, which modalities to employ 
for surveillance. In the U.S., there are surveillance guidelines from the NCCN and ASCO. 
These recommendations differ slightly as a result of differences in results of included 
clinical trials25 used to form guideline recommendations. Results from trials do not give a 
consistent answer to questions about an optimal surveillance program, and importantly, do 
not provide definitive evidence on outcomes related to early detection of recurrent disease or 
second primary tumors.
For survivors of colon and rectal cancers, NCCN recommends the following surveillance 
schedule which we endorse (see Table 1).7 For survivors of stage I cancers, colonoscopy is 
recommended 1 year after resection unless no preoperative colonoscopy occurred due to 
emergent presentation, in which case colonoscopy is recommended 3–6 months after 
surgery. If no abnormalities are detected, repeat colonoscopy is then recommended at 3 
years and then every 5 years thereafter.
Generally, ASCO agrees with the NCCN recommendations, but does not recommend the 
colonoscopy at 3 years. Rather, ASCO recommends colonoscopy every 5 years after the 
initial post-therapy colonoscopy. Detection of adenomatous polyps during surveillance will 
necessitate more frequent follow-up.
Recommendation 3: CRC survivors should receive a history and physical every 3–6 
months in the first 2 years and every 6 months in years 3–5, and annually after 5 years. 
Level of Evidence = 2A
For survivors of stage II and III cancers, for the first 2 years, physicians should take the 
patient’s history and conduct a physical examination as an opportunity to identify 
symptoms, offer counseling, and coordinate posttreatment care.
Recommendation 4: Carcinoembryonic antigen (CEA) testing should be conducted every 
3–6 months for the first 2 years and every 6 months for years 3–5 for those with T2 or 
greater lesions. CEA is not recommended after 5 years. Level of Evidence = 2A
For the first 2 years carcinoembryonic antigen (CEA) testing is recommended every 3–6 
months. Over the next 3 years, CEA testing is recommended every 6 months for T2 or 
greater lesions when the potential exists for further therapeutic intervention of recurrent 
disease. After 5 years, routine CEA is not monitored.
Recommendation 5: Chest/abdominal/pelvic CT should be performed every 12 months 
(stages I-III) or every 3–6 months (stage IV, NED) for up to 5 years. PET-CT is not 
recommended and routine CT is not recommended after 5 years. Level of Evidence = 2A
In addition, for stage III cancer, annual chest/abdomen/pelvis CT scans are recommended 
for up to 5 years. After 5 years, routine CT scans are not recommended. Routine use of 
PET/CT is not recommended in this setting.
In contrast to the NCCN recommendations, ASCO recommends CT scans of the abdomen 
and chest annually for only 3 years for CRC survivors. For rectal cancer survivors, a pelvic 
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CT scan is also recommended, and the oncologist’s judgment should be used to determine 
the frequency of pelvic scans based on recurrence risk in patients (typically every 6–12 
months for 2–3 years, then annually until 3–5 years from surgery). PET scans are not 
recommended as an acceptable substitution.
Recommendation 6: Survivors of stage IV with no evidence of disease following treatment 
should receive CT scans of the chest/abdomen/pelvis every 3–6 months in the first 2 years 
and then every 6–12 months in years 3–5. Level of Evidence = 2A
For survivors of stage IV cancer with no evidence of disease following treatment, similar 
surveillance practices are recommended except that the interval between CT scans should be 
shorter. CT scans of the chest/abdomen/pelvis are recommended every 3–6 months in the 
first 2 years and then every 6–12 months in the next 3 years. As with other stages, routine 
CT scans beyond 5 years or routine PET-CT scans at any interval are not recommended.
Recommendation 7: Rectal cancer survivors who undergo low anterior resection should 
receive proctoscopy every 6 months for 5 years. Level of Evidence = 2A
Specific to rectal cancer only, the NCCN recommends that proctoscopy be considered every 
6 months for 5 years for patients who undergo low anterior resection. The NCCN guidelines 
also recommend that patients undergo limited endoscopic evaluation of the rectal 
anastomosis to identify local recurrence, but optimal timing for surveillance is currently 
unknown.
The American Society of Clinical Oncology endorsed the Cancer Care Ontario Clinical 
Practice Guideline on surveillance protocols24 for patients with stage II and III CRC. In the 
guideline, shorter intervals of follow-up are recommended for patients at higher risk of 
recurrence (e.g. stage IIIc, genetic syndromes, and CEA fluctuations). A medical history, 
physical examination, and CEA testing should be performed every 3–6 months for 5 years. 
A shorter interval is considered earlier in the surveillance period since 80% of recurrences 
occur in the first two to 2.5 years in patients with a high risk of recurrence. The ASCO Panel 
noted the principles of conditional survival estimates which are based on time already 
survived after diagnosis and treatment. Taking survival time into account allows for 
improved accuracy of prognostication. For CRC, there are very high conditional survival 
rates at 4–5 years after treatment, lending evidence to support “stop dates” for surveillance 
protocols, especially since disease-specific survival is very good after 3 years without 
clinical, serologic, or radiologic evidence of disease recurrence.26
In contrast to the NCCN recommendations, ASCO recommends CT scans of the abdomen 
and chest annually for only 3 years for CRC survivors. For rectal cancer survivors, a pelvic 
CT scan is also recommended, and the oncologist’s judgment should be used to determine 
the frequency of pelvic scans based on recurrence risk in patients (typically every 6–12 
months for 2–3 years then annually until 3–5 years from surgery). PET scans are not 
considered an acceptable substitution.
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SCREENING FOR SECOND PRIMARY CANCERS
Recommendation 8: CRC survivors should receive age- and sex-appropriate screening for 
patients with an average risk, except for female CRC survivors with Lynch Syndrome (see 
Recommendation 9) Level of Evidence = 2A
Screening for other malignancies, such as breast, cervical, prostate, or lung cancer, should be 
continued for CRC survivors according to age, gender, and risk factor criteria as per ACS 
guidelines.27 In addition, some CRC survivors have an elevated risk of second primary 
cancers due to genetic factors, and therefore should undergo a more intensive regimen of 
screening. Table 2 summarizes the ACS screening recommendations for each of these 
cancers among average-risk individuals.27
Patients should not undergo cancer screening without first having a discussion with their 
primary care clinician about the risks, benefits, and limitations of the particular screening 
modalities and implications of positive screening tests. This is as true for cancer survivors as 
for the general population. In considering the benefits of screening, primary care clinicians 
and patients should consider the patient’s overall health and life expectancy, and whether 
any patient characteristics place the patient at elevated risk for a specific cancer type.
When possible, primary care clinicians should take the opportunity to acknowledge to 
patients when professional society recommendations disagree. Such discordance is most 
notable in the cases of breast and prostate cancer screening recommendations. While ACS 
currently recommends annual mammography beginning at age 40,28 updated guidelines are 
expected to be released later this year. The U.S. Preventive Services Task Force (USPSTF) 
provides a far more conservative recommendation of beginning biennial mammography at 
age 50 and does not support teaching breast self-examination at the time of this writing. 
Given an average age of CRC diagnosis of 68,17 it is likely that mammographic screening 
will be indicated for a substantial portion of female survivors regardless of the guideline 
followed. For men, USPSTF recommends against routine prostate cancer screening. ACS 
suggests that patients and their primary care clinicians make the decision as to whether to 
screen based on an adequate understanding of the harms (overdiagnosis, overtreatment, false 
positive tests, complications of testing and treatment), benefits (decreased likelihood of late-
stage diagnosis of prostate cancer), and uncertainties of screening.29
Women with Lynch Syndrome
Recommendation 9: Female CRC survivors with Lynch Syndrome should 
receive annual endometrial sampling and transvaginal ultrasound. Level of 
Evidence = 2A—Women with Lynch Syndrome, also known as hereditary non-polyposis 
colorectal cancer (HNPCC), constitute a group with a clearly elevated risk for subsequent 
cancer diagnoses. These women have a 27% to 71% lifetime risk of endometrial cancer—
greater than that of CRC—and a 3% to 14% lifetime risk of ovarian cancer.30,31 Therefore, 
based on expert opinion, ACS suggests that women who are confirmed carriers of a Lynch 
Syndrome mutation or who are likely carriers based on mutation status or incidence patterns 
of family members begin screening with annual endometrial biopsy at age 35.27
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Regardless of HNPCC or CRC status, endometrial sampling has a sensitivity of 99.6% in 
postmenopausal women and 91% in premenopausal women for detection of endometrial 
carcinoma32 and is minimally invasive. Transvaginal ultrasound (TVUS) alone is not a 
reliable screen for endometrial cancer in premenopausal women given highly variable 
endometrial thickness during the menstrual cycle. Its sensitivity in asymptomatic 
postmenopausal women is approximately 83%,33 considerably lower than that of biopsy in 
this group, though it is also thought to be useful for detection of ovarian neoplasms. 
Evidence does support the effectiveness of prophylactic hysterectomy and oophorectomy as 
a means of prevention for both endometrial and ovarian cancer in women with HNPCC.34 
For early detection of ovarian cancer, a 1994 NIH consensus panel recommended at least 
annual rectovaginal examination, CA-125 assessment, and TVUS in women with HNPCC 
and certain other cancer syndromes until age 35, at which time they advocated bilateral 
oophorectomy.35 This recommendation was based on the significantly increased risk of 
ovarian cancer in these patients. Finally, endometrial biopsy should be performed in any 
woman with Lynch Syndrome who reports irregular or postmenopausal vaginal bleeding.36
ASSESSMENT AND MANAGEMENT OF PHYSICAL AND PSYCHOSOCIAL 
LONG-TERM AND LATE EFFECTS OF COLORECTAL CANCER AND ITS 
TREATMENT
The risk of physical long-term and late effects following therapy for CRC is associated with 
several factors, including: a) type of primary tumor, b) type of chemotherapy, c) duration and 
dose of treatment(s) (increasing cumulative dose and duration of therapy increases the 
potential risk), and d) age of patient during treatment. Commonly used chemotherapy and 
biotherapy agents used to treat CRC include 5-fluorouracil (5-FU), oxaliplatin, and 
capecitabine. These drugs have been administered to patients in different combinations and 
at varying dosages and lengths of time, which may relate to the possible long-term and late 
effects. Primary care clinicians should refer to the patient’s cancer treatment summary for 
the specific drugs and doses. Table 3 lists potential physical and psychosocial long-term and 
late effects associated with surgery, radiation, and chemotherapy, which are described in the 
rest of this section.
Bowel/Gastrointestinal Issues
Recommendation 10: Primary care clinicians should ask CRC survivors about 
whether they are experiencing diarrhea, rectal bleeding, rectal incontinence or 
other bowel dysfunction and treat symptoms similar to those in the general 
population. Level of Evidence = III—Chronic diarrhea, i.e. diarrhea lasting longer than 
four weeks, which limits activities and negatively impacts QoL, is one of the most common 
long-term conditions, affecting almost half of CRC survivors.37 Among patients who 
undergo low anterior resection (LAR) for rectal cancer, and other lower surgical 
anastomoses, bowel dysfunction is common including increased stool frequency, bowel 
incontinence and perianal irritation, decreased stool and flatus discrimination, and more 
incomplete evacuations.38,39 Rates of bowel problems are significantly increased in rectal 
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cancer survivors treated with pelvic radiation, regardless of whether it was administered 
preoperatively or postoperatively.40,41
Empirical support to guide optimal management of bowel problems is limited (level III). 
However, anti-diarrheal medications such as Loperamide (Imodium) or diphenoxylate/
atropine (Lomotil) are common first-line treatment for chronic diarrhea after radiation 
therapy. Dietary adjustments, especially elimination of raw vegetables, can be of benefit.42 
Low-fat diets, probiotic supplementation, and elemental diets also may be beneficial among 
patients treated with pelvic radiation.43 Persistent symptoms may necessitate referral to 
gastroenterology. Options for treatment of fecal incontinence include medical therapy such 
as bulking agents or antidiarrheal medications to reduce stool frequency and improve stool 
consistency, biofeedback therapy to improve control of the pelvic floor and abdominal wall 
musculature, and surgery.
Cardiovascular Effects
Recommendation 11: Monitor CRC survivors who are obese or who have had 
prior coronary artery disease and received 5-fluorouracil or capecitabine for 
cardiovascular disease. Level of Evidence = 0—The risk of cardiovascular 
morbidity does not appear to be increased in long-term CRC survivors. In a large British 
cohort study, Khan and colleagues did not observe an excess risk of heart failure or coronary 
artery disease among CRC survivors.44 Nevertheless, there are some important aspects 
regarding the cardiovascular system in CRC survivors that should be noted. It has long been 
recognized that 5-fluorouracil can induce acute endothelial dysfunction, generally 
manifested as chest pain but rarely resulting in an acute myocardial infarction45,46 Therapy 
with capecitabine, a metabolite of 5-fluorouracil, has also rarely resulted in acute myocardial 
infarction.47 Individuals with pre-existing coronary artery disease are at increased risk for 
this acute toxicity.45–47 Fortunately, once therapy is complete, there does not appear to be 
any lasting cardiovascular risk attributable to these two anti-metabolite agents. To date, there 
has not been convincing evidence, beyond occasional case reports, of acute or long-term 
cardiotoxicity associated with oxaliplatin therapy.
While adjuvant therapy for CRC appears to have a relatively low risk for acute or chronic 
cardiotoxicity, there are indirect pathways within a subset of CRC survivors which may 
hasten the progression of cardiovascular disease (CVD). Obesity and sedentary lifestyles are 
associated with an increased risk of CRC.48,49 Thus, it should not be surprising that in a 
large population-based cohort study, Hawkes and colleagues found that CVD was diagnosed 
by 36 months after the cancer diagnosis in 16% of survivors without known pre-existing 
disease. The primary risk factor for developing hypertension, diabetes, and ischemic heart 
disease was obesity at the time of CRC diagnosis and persistent sedentary lifestyles.50 In a 
recent study, Cramer et al reported that CRC survivors, regardless of whether they were 
treated with adjuvant therapy or not, had substantially reduced exercise capacity. This theme 
of diminished exercise capacity and cardiorespiratory fitness is common across cancer 
groups and is a key catalyst, when combined with pre-existing obesity and lifelong sedentary 
behaviors, in the development of CVD.51 Thus, it is imperative that primary care clinicians 
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counsel CRC survivors regarding the well-studied adverse impact of obesity and sedentary 
behaviors and the critical need for modifications in what often have been lifelong habits.
Cognitive Function
Recommendation 12: Screen for cognitive problems, and assess depression 
and anxiety that may worsen cognition and refer for treatment. Level of 
Evidence = 0—Patients have reported changes in cognitive function attributed to cancer 
treatment with chemotherapy for over 20 years, though the mechanism is still not well 
understood.52 The majority of studies focus on breast cancer patients, so there is a paucity of 
data on other cancers, however, a national cross-sectional study looked at self-reported 
memory problems and found that patients who had undergone treatment for cancer were 
40% more likely to report memory problems than those without cancer, regardless of the 
type of cancer or treatment.53 In a prospective, population-based cohort of CRC survivors, 
chemotherapy was associated with worsening cognitive function, particularly for individuals 
under age 70.54
The symptoms reported by patients complaining of cognitive decline vary but may include 
decreased executive functioning skills, slower processing time or reaction response, 
diminished organizational skills, loss of language or math skills, and/or difficulty with 
concentration or attention. These often translate into lower health-related QoL scores, 
especially as patients transition back to work.55 These symptoms can be difficult to interpret 
clinically as there is often discordance between the subjective complaints of memory loss 
and objective testing. Memory impairment may be confounded by physical symptoms 
associated with treatment such as fatigue or pain as well as mental health concerns (stress, 
anxiety or depression). The NCCN guidelines on survivorship care suggest screening for 
treatable causes that may worsen cognitive impairment such as depression and anxiety, 
though data are lacking for evidence-based recommendations regarding routine screening for 
cognitive decline in this population.
For patients that report a change in memory or cognitive function, there are a few tools 
including the Mini Mental Status Exam (MMSE) or the Functional Assessment of Cancer 
Therapy-Cognitive (FACT-Cog) that may be used for screening. A caveat of these screening 
tools is that they are not sensitive at determining deficits in executive functioning, so they 
may underestimate cognitive decline.55 For positive screens, the next step would be a 
referral for formal neurocognitive testing. Neurocognitive testing can quantify and define 
specific problems that may impact activities of daily living or their work which can be 
helpful for patients to understand.
Unfortunately, there are no proven treatments for cognitive impairment related to cancer 
treatment; however, referral for cognitive rehabilitation strategies, e.g. those used for patients 
after strokes may be helpful and studies testing the effects of physical activity on cognition 
are ongoing.
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Recommendation 13: Ask CRC survivors if they are experiencing symptoms 
of mucositis, loss of taste or dry mouth and treat similar to population with 
average risk. Level of Evidence = 0—In a prospective cohort study of CRC survivors, 
loss of taste and dry mouth were found to be significant late effects in patients who had 
received chemotherapy as measured by QoL scores 5 years posttreatment.54 Dry mouth can 
lead to tooth decay, mouth sores or gum disease. Empirical support for recommendations is 
lacking; however, good oral hygiene (brushing teeth with fluoride containing toothpaste, 
flossing regularly, etc.) can prevent these complications but if the symptoms are severe, 
referral to a dentist is recommended for further evaluation and management.
Distress / Depression / Anxiety
Recommendation 14: Screen CRC survivors for psychosocial distress, 
depression and anxiety using a validated screening tool; special attention 
should be paid to survivors with a stoma, and those who report sexual 
dysfunction. Level of Evidence = I/0 (psychosocial screen), IIA (stoma)
Recommendation 15: Refer patients to the appropriate mental health 
professionals or resources in the community as indicated. In addition, follow-
up with the survivor to assess adherence and ensure that the need was met, 
identify potential barriers, and seek alternative approaches as needed. Level 
of Evidence = I—Where appropriate, these guidelines leverage the ASCO guideline 
adaptation of a Pan-Canadian Practice Guideline on Screening, Assessment, and Care of 
Psychosocial Distress (Depression, Anxiety) in Adults With Cancer.11
Many cancer survivors report ongoing difficulties in recovery and returning to ‘normal’ 
following treatment.16,17,19 Some survivors of cancer experience fear of recurrence,56 
contributing to significant mental health problems for which they already have an increased 
risk, including distress, depression, and anxiety.57,58 Prevalence estimates for anxiety, 
depression, and distress in cancer survivors are widely variable, the result of inconsistency in 
the use of measurement tools and differences in methodological approaches, such as the 
choice of comparators from the general population. However, among cancer survivors 
generally, the estimated prevalence of anxiety and depression is 17.9% and 11.6%, 
respectively.59 Among CRC survivors specifically, an estimated 24% report depression 
scores on a standard screening tool high enough to warrant evaluation for clinical 
depression.60 Furthermore, 8% of CRC survivors experience distress severe enough to 
require follow-up.60
Studies suggest that CRC patients and survivors fitted with stoma devices report higher 
levels of depression and anxiety, poorer social functioning, more problems with body image, 
and more side effects from chemotherapy, compared to those without a stoma. For example, 
a prospective study of 249 CRC patients assessed at 3, 6, 12, and 24 months, reported poorer 
QoL in stoma patients, who demonstrated significantly greater impairments on sexual 
functioning and diminished capacity to perform roles.61 These problems were most 
pronounced among male CRC survivors with a stoma. The timing of the stoma procedure 
was an important factor; patients whose stoma was made during the primary procedure fared 
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better than patients whose stoma was made some time after the initial operation.61 Thus, it is 
recommended that primary care clinicians pay particular attention to those CRC survivors 
with a stoma, especially those whose stoma was made later in the treatment trajectory and 
male survivors, who may experience significantly greater impairments in functioning and 
overall QoL.
In order to provide timely and appropriate support for their patients with a history of CRC, 
primary care clinicians should be familiar with the mental health concerns they may 
experience, the tools to screen for and assess these problems, and the resources at their 
disposal to care for their patients. Primary mental health issues revolve around fear of 
recurrence,56 distress, depression, and anxiety. The NCCN defines distress as “a multi-
factorial unpleasant emotional experience of a psychological (cognitive, behavioral, 
emotional), social, and/or spiritual nature that may interfere with the ability to cope 
effectively with cancer, its physical symptoms and its treatment.”62 A well-known tool for 
initial screening is the distress thermometer ((Figure 2: NCCN Distress Thermometer and 
Problem List, Figure (DIS-A), from the NCCN Clinical Practice Guidelines in Oncology 
(NCCN Guidelines®) for Distress Management V.2.2014)) which is similar to the rating 
scale used to measure pain: 0 (no distress) to 10 (extreme distress). A score of four or 
higher63 suggests a level of distress that has clinical significance. Additionally, a 38-item 
Problem List (Figure 2) asks patients to identify their problems in five categories: practical, 
family, emotional, spiritual/religious, and physical. These tools are available from the NCCN 
Guidelines for Distress Management (http://www.nccn.org/professionals/physician_gls/pdf/
distress.pdf).62 Similarly, the Survivor Unmet Needs Survey (SUNS) and the Short-Form 
Survivor Unmet Needs Survey (SF-SUNS) can be utilized to distinguish between problems 
which survivors experience and problems which they desire help in managing across a range 
of life areas, including financial concerns, information and access and continuity of 
care.64,65
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest 
while anxiety is an intense, excessive, and persistent worry and fear about everyday 
situations.66–68 Both depression and anxiety can initially be screened using a variety of 
instruments. One commonly used measure is the validated Hospital Anxiety Depression 
Scale (HADS). The HADS is a 14-item self-report instrument that consists of two distinct 
scales, one for depression and one for anxiety, each scored from 0 to 3, with a final score 
between 0 and 21. A score of 9 or higher on either scale suggests a level of depression or 
anxiety that has clinical significance.69
Another validated instrument that may be used to screen for depression in cancer survivors 
is the CES-D Scale (http://www.chcr.brown.edu/pcoc/cesdscale.pdf). This scale is 20 
questions; each scored 0 to 3, concerning emotions and feelings over the past week.70,71 A 
score of 16 or higher suggests a level of depression that has clinical significance.72 This tool 
identifies significantly more clinical cases than the HADS in similar populations, including 
both true cases and false positives, with more variable results.72
Treatment of anxiety and depression is effective in people with cancer, therefore if a patient 
has a clinically significant score on any of the previously discussed instruments, it is 
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recommended that primary care clinicians refer and/or connect patients to the appropriate 
psychosocial oncology specialists, mental health professionals and/or resources in the 
community.7 After referring to the appropriate resource(s), primary care clinicians should 
follow-up with patients to check their adherence. If a patient has difficulties adhering to 
recommendations, primary care clinicians should work to help identify these challenges and 
find a way for the patient to overcome these obstacles before discussing alternative 
interventions to help the patient comply.11 The American Psychosocial Oncology Society 
(www.apos.org) can help primary clinicians identify these resources. The efficacy of 
psychosocial support for patients including those with CRC is supported by one RCT 
showing a survival benefit for those who received these services.73 Other evidence for 
psychosocial interventions comes from observational studies linking poor emotional well-
being and survival.74 Exercise has also been shown to improve well-being in cancer 
survivors, as documented in a Cochrane review.75
Fatigue
Cancer-related fatigue (CRF) is a potential long-term effect of chemotherapy that is 
prevalent in cancer survivors and often causes significant disruption in functioning and 
QoL.24 NCCN defines fatigue as, “a distressing, persistent, subjective sense of physical, 
emotional, and /or cognitive tiredness or exhaustion related to cancer or cancer treatment 
that is not proportional to recent activity and interferes with usual functioning.”76 Fatigue is 
reported by patients more frequently than any other symptom during the course of cancer 
and its treatment77–81 and is often the most severe and most bothersome symptom reported 
due to its persistence and interference with daily activities.82–84 In a multicenter study of 
cancer survivors (patients with complete remission or no evidence of disease, and not 
currently receiving treatment), researchers observed a 23% prevalence of fatigue in short-
term (≤5 years; n=117) and 43% in long-term (≥to 5 years; n=23) CRC survivors. 27% of 
CRC survivors reported moderate to severe fatigue.77 29% of cancer survivors (for all four 
cancer types combined) reported moderate/severe fatigue that was associated with poor 
performance status and a history of depression. Gender was not found to be a significant 
factor among CRC survivors.77
Recommendation 16: Assess with a validated fatigue instrument, recommend 
physical activity similar to that which is recommended for the general 
population, and refer to specialists for psychosocial support or rehabilitation 
as indicated. Level of Evidence = I—The high prevalence of moderate to severe CRF 
in survivors warrants routine screening, assessment, and management of patient-reported 
fatigue. ASCO recommends that clinicians should screen every patient for the presence of 
CRF and gauge its severity periodically throughout long-term survivorship.24 If present, 
fatigue should be assessed quantitatively on a 0 to 10 scale (0=no fatigue and 10=worst 
fatigue imaginable); those patients with a severity of more than 4 should be further evaluated 
by a history and physical examination.24 For patients who report moderate to severe fatigue, 
comprehensive assessment should be conducted, and medical and treatable contributing 
factors addressed.
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Cancer-related fatigue typically has several different contributing factors in any one patient. 
Primary care clinicians should work with patients and caregivers to improve assessment and 
identify management strategies. Managing CRF includes consistent, reliable screening and 
assessment using a validated instrument and patient-report; treatment of comorbidities that 
may be a contributing factor; and multimodal and individually tailored interventions (e.g. 
exercise, psychoeducational and self-management strategies, efforts to manage concurrent 
symptoms and improve sleep quality, medications and complementary therapies) to improve 
patient-reported symptoms.19,76,85,86 Patient-report is important to fatigue assessment.76,87 
Fatigue management should be initiated when patients rate their fatigue as moderate or 
severe. A single screening question may be efficient to quickly screen for fatigue in clinical 
practice to identify patients who may benefit from further multifactorial evaluation.88 
Various patient self-report measures of CRF are available.85 Institutional tools exist such as 
the M.D. Anderson Symptom Inventory (MDASI), a well-validated multi-symptom 
assessment tool that utilizes a numeric scale of 1 to 10 to rate patient-reported fatigue 
severity and symptom interference with functioning77,89,90 National tools including the 
Brief Fatigue Inventory for rapid assessment of fatigue severity,82 FACT G-7 (Figure 3: 
Functional Assessment of Cancer Therapy – General – (7 item version; be used with patients 
of any tumor type) ((FACT G-7 (Version 4))) a rapid version of the Functional Assessment 
of Cancer Therapy-General (FACT-G) for monitoring symptoms and concerns,78 the FSI to 
assess intensity, frequency, and disruptive impact on QoL,91 the MFSI-SF to assess 
multidimensional manifestation of fatigue,92 and the FACT-C (Figure 4: FACT-C) used to 
assess HRQOL (combines the FACT-G assessment with additional CRC-specific 
measurement).93,94
In terms of management strategies, evidence indicates that physical activity interventions, 
psychosocial interventions, and mind-body interventions may reduce CRF in posttreatment 
patients. There is limited evidence for use of psychostimulants in the management of fatigue 
in patients who are disease-free after active treatment.
Numerous RCTs and meta-analyses document that physical activity improves aerobic 
capacity, prevents muscle loss and deconditioning, and it may produce favorable effects on 
sleep, mood, body composition, and the immune system and cytokine milieu, while 
promoting self-efficacy (evidence level I).75,95–97 Primary care clinicians should counsel 
survivors to engage in regular physical activity, avoid inactivity and return to normal daily 
activities as soon as possible following diagnosis.
For chronic CRF, primary care clinicians should refer survivors to rehabilitative specialists 
to address lingering fatigue, and provide supportive care recommendations.
General supportive care recommendations for patients with fatigue include optimizing 
nutritional status and preventing weight loss, balancing rest with physical activity, and 
attention-restoring activities such as exposure to natural environments and pleasant 
distractions like music.76
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Chemotherapy-induced peripheral neuropathy (C-IPN) is a potential long-term effect of 
neurotoxicity caused by chemotherapeutic agents. Chemotherapy-induced peripheral 
neuropathy can lead to permanent symptoms and disability in upwards of 40% of cancer 
survivors negatively affecting QoL.98 Oxaliplatin is commonly considered standard therapy 
in CRC adjuvant chemotherapy regimens. Oxaliplatin-induced peripheral neuropathy (O-
IPN) is common among survivors one or more years posttreatment.99–103 Cumulative 
oxaliplatin-induced peripheral neuropathy is reported to be partially reversible in 
approximately 80% of patients and completely resolves in approximately 40% at 6 to 8 
months posttreatment. Chronic cumulative O-IPN persists posttreatment and severe O-IPN 
resolves approximately 13 weeks posttreatment in most patients.99,104 Signs and symptoms 
may continue to develop and worsen for an additional 2 to 6 months posttreatment, also 
known as “coasting.”12,105 Sensory nerve dysfunction is most common. The large sensory 
nerves are affected, leading to symptoms of paresthesias, such as “pins and needles” or 
tingling, numbness, pressure, cold, and warmth that are experienced in the absence of a 
stimulus; dysesthesias or distortion of sensory perception resulting in an abnormal and 
unpleasant sensation, and numbness in the hands and feet.106–108 Clinical exam may 
uncover impairment in perception of touch, vibration, and proprioception. Nerve endings in 
the hands and feet are usually affected earliest by neurotoxicity in a symmetrical, length-
dependent manner affecting the longest nerve fibers in the body first. Disabling symptoms 
like sensory ataxia, pain and severe numbness can interfere with functional ability and QoL.
Recommendation 17: Assess with Total Neuropathy Score or other validated 
tool for CRC survivors who received oxaliplatin and refer to rehabilitation and 
pain management specialists as indicated. Level of Evidence = 0—Pre-existing 
factors that may increase patient risk for developing O-IPN include pre-existing neuropathy, 
alcoholism and diabetes mellitus.99,100,109 Higher cumulative drug dose is a possible 
indicator for developing long-term O-IPN. A descriptive study reported that persistent 
grades 2 and 3 O-IPN was more common in patients who received a cumulative dose of 
more than 900 mg/m2 suggesting influence of oxaliplatin administration on long-term O-
IPN.99,110
Currently no standardized assessment tool or questionnaire for O-IPN has been used in 
studies of O-IPN. The National Cancer Institute-Common Terminology Criteria for Adverse 
Events (NCI-CTCAE) or “common toxicity criteria” (toxicity graded as mild- Grade 1, 
moderate-Grade 2, severe-Grade 3)108 has been applied more widely; in addition to the 
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Oxaliplatin-
Specific Neurotoxicity questionnaire (FACT/GOG-Ntx), a reliable and valid instrument for 
assessing the impact of neuropathy on health-related QoL; a neuropathic symptom 
questionnaire; and neurophysiological examinations (e.g. nerve conduction 
studies).99,107,111 Use of the Total Neuropathy Score (TNSc) (Figure 5: Total Neuropathy 
Score) which does not require specialized equipment or training may be more suitable for 
clinical practice.
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At present strong evidence for standard therapy or neuroprotective strategy (e.g. topical 
agents, antidepressants, and or antiepileptics) for O-IPN is lacking. Prevention is key to 
preventing O-IPN by identifying patients who may be at increased risk of developing severe 
or persistent forms of O-IPN.99
Although C-IPN trials are inconclusive regarding tricyclic antidepressants (such as 
nortriptyline), gabapentin, and a compounded topical gel containing baclofen, amitriptyline 
HCL, and ketamine, these agents may be offered on the basis of data supporting their utility 
in other neuropathic pain conditions given the limited other C-IPN treatment options.12
To treat existing C-IPN, the best available data support a moderate recommendation for 
treatment with duloxetine. The effect of duloxetine was studied in a randomized, placebo-
controlled, cross-over trial of 231 patients with C-IPN. Patients received 30 mg of 
duloxetine or placebo for the first week and 60 mg of duloxetine or placebo for 4 more 
weeks. Patients who received duloxetine reported a significant decrease in average pain 
compared with those who received placebo (P = .003). In addition to a decrease in pain, data 
from the trial also supported that duloxetine decreased numbness and tingling 
symptoms.12,112
Primary care clinicians should refer survivors for rehabilitative medicine treatments 
including physical therapy and pain management as needed. For disabling chronic C-IPN, 
primary care clinicians should refer survivors to neurology or to occupational and physical 
therapy.113
Ostomy / Stoma
Recommendation 18: For CRC survivors with a stoma, monitor for sexual 
dysfunction, distress, depression, anxiety and QoL. Refer to specialists for 
support as indicated. Level of Evidence = I—Colon cancer survivors are less likely 
than rectal cancer survivors to need a permanent stoma. To better understand the long-term 
impacts of ostomies on CRC survivors, McMullen et al. conducted a mixed methods study 
of health-related QoL in CRC survivors who were at least 5 years posttreatment and had 
permanent ostomies.114 The qualitative study explored themes in written responses to open-
ended survey questions related to physical, psychological, social, and spiritual domains. 
There were 178 responses to the question, “Many people have shared stories about their 
lives with an ostomy. Please share with us the greatest challenge you have encountered in 
having an ostomy.” Six themes and various subthemes emerged from the content analysis. 
One of the challenges CRC survivors face relates to caring for the ostomy and appliances. 
These challenges include routine ostomy care, achieving bowel regularity, issues with 
leakage, gas, and odor, and skin irritations at the ostomy site. Examples of dealing with the 
ostomy and appliances include finding the right equipment, equipment failures, and dietary 
changes and adaptations. Many of these issues can be addressed by a trained ostomy 
therapist. Patients with an ostomy may benefit from additional psychosocial support to 
adjust to and live with an ostomy appliance. The efficacy of psychosocial intervention 
including patient education is supported by numerous RCTs and a systematic review (level 
I) documenting positive effects on stoma-related knowledge, health-related quality of life, 
and cost-reduction.115
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Recommendation 19: Monitor patients who received pelvic irradiation for 
chronic proctitis and manage symptoms as indicated. Level of Evidence = I—
Chronic pain is one of the uncommon but important sequelae of CRC and its treatment. The 
most important risk factor for development of chronic pain is pelvic irradiation resulting in 
chronic proctitis. Chronic pain is known to contribute to functional limitation and negatively 
impacts the QoL in CRC survivors. While there are no specific guidelines to managing pain 
in the context of CRC survivorship, interventions with pharmacotherapy including the use of 
opioid analgesics,116 utilization of pain management services, if available, and incorporation 
of behavioral interventions/physical activity and/or rehabilitation/physical therapy have 
demonstrated efficacy in pain control in systematic reviews in other cancers or pain 
syndromes (evidence level I).75,117
Sexual Function / Fertility
Recommendation 20: Primary care clinicians should address sexual function 
when managing CRC survivors. For CRC survivors of childbearing age, who 
experience infertility due to treatment, refer for psychosocial support. Level of 
Evidence = 0, IA (oral phosphodiesterase-5 inhibitors in men), IC (vaginal 
moisturizers and lubricants for women)—Colorectal cancer is fairly uncommon 
during the reproductive years. The incidence of CRC is 3.3 and 3.8 per 100,000 persons for 
females and males, respectively, in the U.S. between the ages of 15 and 39 years.17 As of 
2008, it was estimated that there were about 27,000 CRC survivors in the U.S. who were age 
44 or younger.118 Reflecting the increasing incidence of CRC as individuals age, over half of 
this estimate was survivors between 40 and 44 years of age.118,119 Given the relatively small 
number of CRC survivors treated during their reproductive years, there have consequently 
been few studies evaluating gonadal function and infertility following therapy. The primary 
therapy associated with infertility in women with rectal cancer is pelvic radiotherapy.120 
Even with contemporary approaches to minimize the radiation exposure to normal 
surrounding tissues, the ovaries often receive substantial doses unless they are surgically 
transposed prior to radiation.121 With a diminishing primordial follicle pool in women in 
their 30s and 40s, the doses of radiation necessary to induce acute ovarian failure is lower 
than for women treated with pelvic radiation as a child or adolescent. In men, despite 
shielding of the testes, the dose of radiation is often enough to damage the germinal 
epithelium and cause azoospermia.122 In the treatment of other cancer types, 5-fluorouracil 
has not been shown to cause infertility in women or men. Oxaliplatin is moderately 
gonadotoxic.120 In a woman whose primordial follicle pool is diminished by age, treatment 
with oxaliplatin may induce ovarian failure and premature menopause, thereby causing 
infertility.123 Fertility rates in males do not appear to be substantially affected, though this 
remains an understudied area.
While infertility affects a relatively small percent of CRC survivors, sexual dysfunction is a 
problem that spans across the age spectrum. In general, sexual dysfunction is prevalent 
following treatment for CRC, particularly among rectal cancer survivors. Study in this area 
is quite complex. A substantial proportion of individuals are diagnosed with CRC at an age 
when sexual activity is beginning to wane. Thus, to interpret prevalence data or a change in 
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sexual activity, it is important to have a similarly aged non-cancer population. Adding to the 
complexity of studies, surgical and radiation techniques have evolved, often aimed at 
reducing long-term outcomes such as sexual dysfunction while providing adequate local 
control of the tumor. For example, in the mid-1980s, total mesorectal excision (TME) was 
introduced as a surgical technique for resecting rectal cancer, with a goal of preserving 
autonomic nerve function and preventing urologic problems and sexual dysfunction. Thus, 
there are multiple subgroups of CRC survivors, depending upon tumor location, surgical 
technique, having an ostomy, and the use of preoperative radiotherapy. Further complicating 
the study of sexual function in CRC survivors is the fact that key outcomes, and definitions 
of function, are different between males and females, and often different from one study to 
another. Needless to say, the number of adequately powered prospective studies with a non-
cancer comparison population is low. Nevertheless, there are several key findings regarding 
sexual function that have been consistently reported across studies and should be addressed 
in evaluating a CRC survivor.
Even with contemporary surgical approaches intent on sparing autonomic nerve function, 
which is important for erectile function in males, the rectal cancer size and location often 
precludes full preservation of nerve function. In addition, radiotherapy is a frequent method 
of local tumor control for rectal cancer (but not for colon cancer). Thus, in males, sexual 
dysfunction is more common among rectal cancer survivors than following radiotherapy for 
colon cancer.124,125 In a large population-based study of CRC survivors who were 12 to 36 
months following their diagnosis, 25% of rectal cancer survivors reported difficulties with 
sexual matters; 11% of colon cancer reported difficulties.126 Den Oudsten and colleagues 
surveyed 1359 CRC survivors who were a mean age of 70 years at time of study and about 4 
years since their initial diagnosis.127 A higher proportion of male rectal cancer survivors 
reported erectile dysfunction (54%) than the normative (non-cancer) population (27%). 
Similarly, male rectal cancer survivors frequently reported ejaculatory problems (68%). 
Despite these problems, there was no difference in sexual enjoyment between male rectal 
cancer survivors and men in the normative population. Moreover, male CRC survivors were 
fairly similar to the normative population with respect to erectile dysfunction, ejaculatory 
problems, and sexual enjoyment. In a well-designed prospective study of 990 patients 
diagnosed with rectal cancer at a mean age of 64 years and randomized to TME with or 
without preoperative radiotherapy, Lange et al reported several interesting findings.128 
Among men, 20.8% were not sexually active at the time of their cancer diagnosis. Of the 
men who were sexually active at time of cancer diagnosis, 28.5% were no longer active by 
two years after radiotherapy. Postoperative erectile dysfunction and ejaculatory problems 
developed or worsened in 79.8% and 72.2% of men, respectively. Unfortunately, there was 
not a non-cancer comparison population, so it is difficult to know how much normal aging 
influenced these changes. In multivariate models, anastomotic leakage and excessive 
perioperative blood loss (perhaps a proxy for surgical nerve damage) were associated with 
worsening function. While radiotherapy was not independently associated with sexual 
dysfunction, the interval from radiotherapy to last evaluation was likely too short to 
determine the additive effect of radiation.
Female CRC survivors, regardless of whether the cancer was in the colon or rectum, are 
substantially more likely to report sexual dysfunction, including dyspareunia, than women in 
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the normative population.124–127 While vaginal dryness appears to occur with similar 
frequency among colon and rectal cancer survivors, dyspareunia is more common in those 
treated for a rectal cancer.127 In the aforementioned prospective study by Lange and 
colleagues, only 51.7% of female CRC patients were sexually active at time of cancer 
diagnosis.128 Of those who were sexually active, 18.4% were no longer active by two years 
after the cancer diagnosis. Dyspareunia and vaginal dryness developed or worsened over 
time in 59.1% and 56.6% of the women, respectively. A temporary or definitive stoma was 
the only factor in multivariate analysis that was associated with worsening of either 
outcome. While radiotherapy was independently associated with general sexual dysfunction 
in women, it was not associated with the development of dyspareunia or vaginal dryness.
Multiple studies have shown a strong correlation between sexual dysfunction and 
psychosocial distress.129–132 Thus, primary care clinicians should address sexual function 
when managing CRC survivors. Some therapies are available for men and women 
experiencing symptoms or signs of sexual dysfunction. In men, particularly those treated 
with pelvic radiotherapy, Leydig cell dysfunction should be evaluated and testosterone 
replacement initiated if indicated. The efficacy of oral phosphodiesterase-5 inhibitors for 
male survivors experiencing erectile dysfunction has been shown in one RCT.133 Women 
with vaginal dryness may benefit from the use of vaginal moisturizers and water or silicone-
based lubricants during intercourse, as recommended by the International Menopause 
Society for postmenopausal women without a cancer history.134 If available, referral for 
counseling and / or sexual health programs may be beneficial.124,125,132,135
Urinary Bladder Issues
Recommendation 21: Screen CRC survivors for urinary incontinence and 
retention and manage as you would a patient of average risk of urinary 
dysfunction. Level of Evidence = IC—Urinary complications are common after 
treatment for CRC. Both surgery and radiation can affect the bladder and cause symptoms 
such as urinary incontinence or retention that affect QoL scores. Interestingly, the type of 
surgery (open v. laparoscopic) does not seem to make a difference in the Global Rating QoL 
scores.136 However, long term urinary complications were slightly more frequent in patients 
who underwent ostomies v. anastomosis: urinary retention (ostomy 6%, anastomosis 1.3%) 
and urinary incontinence (ostomy 2.1%, anastomosis 0.0%).137
Functional voiding disturbances such as stress, urge or overflow incontinence have all been 
reported postoperatively and may be deemed long-term effects. Urinary retention occurs 
when there is injury to the pelvic nerves during mobilization of the rectum. Newer surgical 
techniques have made this much less common and fortunately this is often transient and does 
not progress as a long-term effect when recognized and treated early in the postoperative 
period. For patients with prolonged urinary retention after the surgery, referral to an 
urologist for urodynamic studies should be done to elucidate the diagnosis. Patients with 
hypocontractile bladders may require clean intermittent catheterization, while patients with 
adherence abnormalities may respond well to medical therapy with anticholinergic 
medications.138
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Stress and urge urinary incontinence are more common with prevalence exceeding 50% up 
to five years postoperatively.139 However, this is difficult to interpret as background rates of 
incontinence in the general population are also high. Evidence-based treatment guidelines 
are lacking for post-surgical incontinence in CRC survivors; thus, recommendations are 
based on interventions used in the general population. Kegel exercises can be helpful for 
stress incontinence due to pelvic floor dysfunction, but pelvic floor strengthening may be 
limited if denervation occurred during surgery.140 Other conservative therapies such as 
dietary modification (limiting caffeine and fluid intake) or medications may also be useful. 
Anticholinergic drugs are effective in stress incontinence and antimuscarinic drugs are used 
for urge or mixed incontinence.
Pelvic radiation used for adjunctive therapy for CRC can lead to fibrosis of the bladder wall, 
weakening of the pelvic floor muscles and thinning of the lining of the bladder. Urinary 
incontinence, frequency, urgency, dysuria or hematuria are manifestations of radiation 
therapy for CRC that may persist after treatment ends in a small number of patients. There is 
no good evidence on which to base treatment guidelines, therefore management is based on 
expert opinion and is aimed at controlling symptoms. For urgency and frequency, avoiding 
foods that irritate the bladder (citrus/tomatoes/caffeine) may be beneficial. Kegel exercises 
or bladder retraining are useful for incontinence. Persistent hematuria after radiation is rare, 
thus a urology referral for cystoscopy may be warranted to look for other causes of 
hematuria.
HEALTH PROMOTION
Recommendation 22: It is recommended that primary care clinicians provide routine 
general medical care and health promotion recommendations, and continue to treat 
patients’ chronic conditions, recognizing that cancer treatments worsen the severity of 
many underlying chronic conditions. Level of Evidence = 0, III (weight); 0, IB (physical 
activity); 0 (nutrition); 0, III (tobacco cessation); 0 (alcohol use)
Health promotion recommendations for CRC survivors are provided in Table 5. Where 
appropriate, these guidelines leverage the ACS Nutrition and Physical Activity Guidelines 
for Cancer Survivors.141
Information
Colorectal cancer survivor and caregiver information needs should be routinely assessed and 
information about the late effects of CRC treatment, as well as information on risk reduction 
and health promotion, should be provided.
There are no completed large randomized trials directly assessing the impact of obesity, 
physical activity, specific dietary patterns or tobacco use on CRC progression or mortality. 
There is, however, a growing body of prospective and observational data supporting 
associations between these factors and outcomes in CRC survivors.
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Obesity is at epidemic proportions in the U.S. and obesity rates of 17% to 35% have been 
reported in trials of adjuvant chemotherapy in patients with colon cancer.142 Increasing 
evidence indicates that being overweight or obese increases the risk of CRC recurrence and 
of being diagnosed with other obesity-related cancers. A number of these studies also 
suggest that obesity reduces the likelihood of disease-free and overall survival.143–145 
Colorectal cancer survivors should consume a well-balanced diet and weight management 
should be considered a priority standard of care. Individuals who recently faced a cancer 
diagnosis are often motivated to live a healthier lifestyle, particularly if the changes are 
linked to a higher likelihood of avoiding a recurrence. For CRC survivors who are 
overweight or obese, primary care clinicians should encourage increased physical activity 
and healthier eating, focusing on lower total calorie intake. Referral to weight loss programs 
and frequent follow-up by the primary care clinician are sensible interventions.
Physical Activity
Evidence suggests that increased physical activity levels are associated with better physical 
functioning, reduced fatigue, increases oxygen consumption and better patient-reported 
QoL.141 A small number of studies also suggest that CRC survivors who increased their 
physical activity from pre- to post-diagnosis may decrease their total mortality risk.146 
Colorectal cancer survivors may experience substantial benefits from increasing exercise, 
affecting multiple domains of well-being. Many cancer survivors may not feel ready to 
engage in the recommended exercise level of 150 minutes per week. Thus, attention should 
be given to helping patients gradually increase their activity levels with the goal of 
exercising 150 minutes per week.
Nutrition
A number of dietary patterns including higher intake of red meat and processed meat, 
refined grains, and sugary desserts have been associated with a statistically significant 
increase in CRC recurrence and poorer overall survival.147,148 Colorectal cancer survivors 
should follow nutritional guidelines to reduce their risk of a second primary cancer, as well 
as reducing their risk for other chronic conditions such as CVD. Following a diet that is high 
in vegetables, fruits and whole grains is ideal and diets should have low amounts of saturated 
fats, as well as appropriate dietary fiber.
Additional diet and nutritional recommendations for CRC survivors based on these ACS 
guidelines include CRC survivors with chronic bowel problems or surgery that affects 
normal nutrient absorption should be referred to a registered dietitian to modify their diets to 
accommodate the changes and maintain optimal health (as described under Bowel/
Gastrointestinal Issues in the Long-Term and Late Effects section of this paper), and ensure 
a sufficient Vitamin D status and consume recommended levels of calcium.149,150
Smoking Cessation
Studies have indicated that smokers who smoked prior to a diagnosis of CRC as well as 
those who smoke after diagnosis are nearly twice as likely to die as a result of their cancer, 
and have more than double the risk of overall mortality compared to non-smokers.151,152 In 
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spite of these risks a recent survey found that nearly 10% of cancer survivors continued to 
smoke more than 9 years after their diagnosis.153
Tobacco cessation is an important part of posttreatment care of cancer patients. Primary care 
clinicians should counsel CRC survivors to avoid tobacco and offer cessation when 
appropriate.
In summary, it is recommended that primary care clinicians follow ACS Guidelines on 
Nutrition and Physical Activity for Prevention and Early Detection of Cancer and Nutrition 
and Physical Activity for Cancer Survivors to inform counseling on routine health 
promotion.
CARE COORINDATION AND PRACTICE IMPLICATIONS
Recommendation 23: Initiate and maintain direct communication with all specialists 
involved in your patient’s oncology care and symptom management. Request a treatment 
summary and follow-up care plan to guide coordination of follow-up care posttreatment. 
Level of Evidence = 0, III (treatment summary and survivorship care plan); 0, IA (care 
coordination for chronic conditions); 0 (psychosocial referral); 0 (rehabilitation referral); 0, 
I (follow-up care regimen)
The clinical follow-up care planning process and coordination among care providers are 
essential to ensure all health needs of the cancer survivor are met. It is recommended that the 
primary care clinician initiate and maintain direct communication among oncology and 
specialty providers regarding clinical follow-up care. This communication should clearly 
specify roles of clinicians related to clinical follow-up care. Patients completing primary 
treatment should be provided with a comprehensive treatment summary and clinical follow-
up care plan (survivorship care plan or SCP) from the primary treating specialist(s) who 
coordinated the oncology treatment. While the use of these tools has been endorsed, there 
are few high quality studies of SCPs. Some have reported that survivor satisfaction with, and 
self-reported understanding of, their SCP were very high. One study found that breast cancer 
survivors with SCPs were better able to correctly identify the clinician responsible for their 
follow-up care, and another suggested a reduction of unmet needs among patients with 
SCPs. Health professionals have cited the time required to develop SCPs (1–4 hours) as a 
significant barrier to their implementation and utilization.154,155
One of the central challenges confronting all health care clinicians dedicated to improving 
care for cancer survivors is the widespread lack of well-defined smoothly functioning inter-
disciplinary care teams. Many primary care clinicians have not focused specifically on what 
it means to serve as the leader or coordinator of a cancer survivor’s clinical team. Others 
believe they do not have the expertise to serve in this role. The need for this type of 
coordination has been widely accepted and is supported by available evidence, even though 
that evidence base is immature. Primary care clinicians must now realize that it is the 
standard of care for call cancer patients to have a treatment summary and a survivorship care 
plan. Accordingly, primary care clinicians should initiate and maintain direct 
communication among patient, specialty providers, and primary care clinicians regarding 
clinical follow-up care, clearly specify roles of clinicians related to clinical follow-up care, 
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and proactively contact the oncology specialist to obtain a treatment summary and clinical 
follow-up care plan. The emergence of new payment models, such as accountable care 
organizations, may facilitate development of this new higher level of coordination.
LIMITATIONS
A significant limitation of this review is the limited evidence-base to provide clear and 
specific recommendations for the prevention and management of long-term and late effects. 
Lack of clinical trials is a limitation of the current state-of-the-science for survivorship and a 
limitation of the recommendations for management indicated in the tables. There are few 
prospective, randomized control trials testing interventions among CRC survivors. The 
majority of the citations characterizing the risk and magnitude of risk of late effects and 
management recommendations rely predominantly on case-control studies with fewer than 
500 participants and reviews that combine studies with varying outcome measures. There 
were several cohort studies that used population-based data to estimate the risk of late 
effects.
Other limitations include lack of patient/consumer participation in the guideline process; 
lack of a radiation oncologist on the expert workgroup; and reliance on previous guidelines 
for surveillance. Additionally, the literature review was not managed by a clinical 
epidemiologist due to limited resources. The literature review and environmental scan were 
conducted by project staff. An ACS librarian and the ACS Principal Investigator for The 
Survivorship Center were consulted for supplemental literature searches. Furthermore, the 
guidelines did not result directly from the development of specific clinical questions asked 
prior to the literature review; and recommendations for inclusion were not systematically 
evaluated through an instrument such as the Rigor of Development subscale of the Appraisal 
for Guidelines for Research and Evaluation (AGREE II).
Management recommendations are based on current evidence in the literature, but most 
evidence is not sufficient to warrant a strong recommendation. Rather, recommendations 
should be seen as possible management strategies given the current limited evidence base.
SUMMARY
Due to the potential significant impacts of cancer and its treatment on CRC survivor health 
and QoL, it is imperative that cancer survivors receive high-quality, comprehensive, 
coordinated clinical follow-up care. This care should focus on both the physical and 
psychosocial impacts and take into consideration the individual’s treatment and needs. 
Historically, the focus of clinical follow-up care has been on screening and surveillance for 
recurrence and new cancers, but it is now clear that it should also entail detection and 
management of the long-term and late impacts. Moreover, cancer survivors need to be 
counseled on health promotion strategies to help minimize or mitigate these impacts. One 
key recommendation made here and elsewhere is that survivors and primary care clinicians 
receive a survivorship care plan, which includes a concise summary of treatment as well as a 
clinical follow-up care plan. This tool facilitates a discussion with the patient and all 
clinicians and presents an opportunity to improve care coordination by clarifying roles.
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Despite gaps in the evidence base regarding critical components of clinical follow-up care, 
enough evidence exists to provide consensus-based guidelines to improve posttreatment care 
until additional evidence can be generated. This guideline on clinical follow-up care for 
CRC survivors is geared toward the diverse group of primary care clinicians who provide 
much-needed care for a wide variety of patients, some of whom may be CRC survivors.
In addition to this article, tools and resources are available to assist primary care clinicians in 
implementing the recommendations. The CA Journal offers the CA Patient Page, a tool to 
help patients understand how to use the guidelines to talk to their doctor about care 
coordination, healthy behaviors, surveillance and screening, and symptom management. 
Primary care clinicians can access the free CA Patient Page for CRC survivors or download 
it at (insert URL). The Survivorship Center offers The GW Cancer Institute’s Cancer 
Survivorship E-Learning Series for Primary Care Providers (The E-Learning Series), a free, 
innovative online continuing education program to educate primary care providers about 
how to better understand and care for survivors in the primary care setting. Continuing 
education credits (CEs) are available at no cost to physicians, nurse practitioners, nurses and 
physician assistants for each 1-hour module. Learn more about The E-learning Series at 
cancersurvivorshipcentereducation.org.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Colorectal Cancer Incidence and Mortality Rates* by Race/Ethnicity and Sex, United 
States, 2006–2010
Description:
Colorectal cancer incidence and mortality rates by race/ethnicity and sex during 2006 
through 2010.
Credits:
• Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J 
Clin. 2014;64(2):104–117.
• Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat 
Database: Mortality-All COD, Aggregated With State, Total US (1969–2010) 
<Katrina/Rita Population Adjustment>. Bethesda, MD: National Cancer 
Institute, Division of Cancer Control and Population Sciences, Surveillance 
Research Program, Cancer Statistics Branch; 2013. Released April 2013; 
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underlying mortality data provided by National Center for Health Statistics, 
2013.
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Figure 2. NCCN Distress Thermometer and Problem List, Figure (DIS-A), from the NCCN 
Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Distress Management V.
2.2014
Description:
NCCN Distress Thermometer and Problem List, Figure (DIS-A), from the NCCN Clinical 
Practice Guidelines in Oncology (NCCN Guidelines®) for Distress Management. The 
NCCN Distress Management Panel developed the Distress Thermometer, a now well-known 
tool for initial screening, which is similar to the successful rating scaled used to measure 
pain: 0 (no distress) to 10 (extreme distress). The DT serves as a rough initial single-item 
question screen, which identifies distress coming from any source, even if unrelated to 
cancer. The receptionist can give it to the patient in the waiting room. The screening tool 
developed by the NCCN Distress Management Panel includes a 39-item Problem List, 
which is on the same page with the DT. The Problem List asks patients to identify their 
problems in five different categories: practical, family, emotional, spiritual/religious, and 
physical. The panel notes that the Problem List may be modified to fit the needs of the local 
population.
Credits:
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• Reproduced with permission from the NCCN Clinical Practice Guidelines in 
Oncology (NCCN Guidelines®) for Distress Management (V.2.2014). © 2014 
National Comprehensive Cancer Network, Inc. Available at: NCCN.org. 
Accessed (April 27, 2015). To view the most recent and complete version of the 
NCCN Guidelines®, go on-line to NCCN. org.
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Figure 3. Functional Assessment of Cancer Therapy – General – (7 item version; be used with 
patients of any tumor type) ((FACT G-7 (Version 4))
Description:
General measure for functional assessment of cancer therapy to be used with patients of any 
tumor type.
Credits:
• Cella DF, Tulsky DS, Gray G, Sarafian B, et al. The Functional Assessment of 
Cancer Therapy scale: development and validation of the general measure. J Clin 
Oncol. 1993;11(3), 570–579. http://www.facit.org/FACITOrg/Questionnaires.
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Cancer specific measure for functional assessment of cancer therapy to be used with patients 
with colorectal cancer.
Credits:
• Cella DF, Tulsky DS, Gray G, Sarafian B, et al. The Functional Assessment of 
Cancer Therapy scale: development and validation of the general measure. J Clin 
Oncol. 1993;11(3), 570–579. http://www.facit.org/FACITOrg/Questionnaires.
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Figure 5. Total Neuropathy Score
Description:
The total neuropathy score is a validated measure of peripheral nerve function.
Credits:
• DR Cornblath, Chaudhry V, Carter K, et al. Total neuropathy score: validation 
and reliability study. Neurology. 1999;53(8):1660.
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Table 1
Surveillance Guidelines for Colorectal Cancer Recurrence and Screening and Early Detection of Second 
Primary Cancers (Stage I–III)
Guideline (Level of Evidence for this table is 2A*)
1–2 Years Post-treatment*:
• H & P every 3–6 months
• CEA every 3–6 months
• Chest / abdominal / pelvic CT every 12 months (stages I–III); every 3–6 months (stage IV, NED)
• Colonoscopy in 1 year; if advanced adenoma, repeat in year 2
• Proctoscopy (rectal cancer only) repeat every 6 months
3–5 Years Post-treatment*:
• H & P every 6 months
• CEA every 6 months for T2 or greater
Chest / abdominal / pelvic CT every 12 months (stages I–III at high risk for recurrence and stage III); every 6–12 months (stage 
IV, NED)
• Colonoscopy in year 4; if no advanced adenoma, repeat every 5 years
• Proctoscopy (rectal cancer only) repeat every 6 months
5+ Years Post-treatment*:
• H & P annually
• CEA not recommended
• Chest / abdominal / pelvic CT not recommended all stages
• Colonoscopy every 5 years starting 8 years after resection
• Proctoscopy (rectal cancer only) not recommended
NOT Recommended:
• PET-CT Scan
• Routine blood tests (e.g., CBC, liver function test)
• After five years, routine CEA monitoring is not recommended
• After five years, routine CT scans are not recommended
• Routine use of PET/CT is not recommended for any stage
• PET scans are not considered an acceptable substitution for CT scans
Optimal timing unknown:
• Limited endoscopic evaluation of the rectal anastomosis to identify local recurrence.
• Screen survivors for breast, cervical and prostate cancers according to American Cancer Society guidelines.
• Women with known HNPCC genetic mutation, strong family history of HNPCC may be at increased risk for endometrial cancer.
• Counsel all survivors for family history and treat patients with suspected hereditary HPNCC, FAP according to high risk 
screening guidelines.
H & P indicates history and physical; CEA, carcinoembryonic antigen; NED, no evidence of disease; CBC, complete blood count; HNPCC, 
hereditary nonpolyposis colorectal cancer; FAP, familial adenomatous polyposis.
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a
Level of evidence: I, meta analyses of randomized controlled trials (RCTs); IA, RCT of colorectal cancer survivors; IB, RCT based on cancer 
survivors across multiple sites; IC, RCT not based on cancer survivors, but on general population experiencing a specific long-term or late effect 
(e.g., chronic diarrhea, sexual dysfunction, etc.); IIA, non-RCT based on colorectal cancer survivors; IIB, non-RCT based on cancer survivors 
across multiple sites; IIC, non-RCT not based on cancer survivors but on general population experiencing a specific long-term or late effect (e.g., 
chronic diarrhea, sexual dysfunction, etc.); III, case study; 0, expert opinion, observation, clinical practice, literature review, or pilot study.
*
National Comprehensive Cancer Network rating indicates that “based upon lower-level evidence, there is uniform consensus that the intervention 
is appropriate.”
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Table 2






Breast Women ages ≥20
y
BSE It is acceptable for women to choose not to do
BSE or to do BSE regularly (monthly) or
irregularly. Beginning in their early 20s, women
should be told about the benefits and limitations of
BSE. Whether a woman ever performs BSE, the
importance of prompt reporting of any new breast
symptoms to a health professional should be
emphasized. Women who choose to do BSE
should receive instruction and have their
technique reviewed on the occasion of a periodic
health examination.
CBE For women in their 20s and 30s, it is
recommended that CBE be part of a periodic
health examination, preferably at least every 3 y.
Asymptomatic women aged ≥40 y should continue
to receive a CBE as part of a periodic health
examination, preferably annually.





Cervical cancer screening should begin at age 21
y. For women aged 21–29 y, screening should be
done every 3 y with conventional or liquid-based
Pap tests. For women aged 30–65 y, screening
should be done every 5 y with both the HPV test
and the Pap test (preferred), or every 3 y with the
Pap test alone (acceptable). Women aged >65 y
who have had ≥3 consecutive negative Pap tests
or ≥2 consecutive negative HPV and Pap tests
within the last 10 y, with the most recent test
occurring within the last 5 y, and women who have
had a total hysterectomy should stop cervical
cancer screening if they no longer have a cervix
and are without a history of CIN2 or a more severe
diagnosis in the past 20 y or cervical cancer ever.
Women at any age should not be screened












Annual, starting at age 50 y. Testing at home with
adherence to manufacturer's recommendation for
collection techniques and number of samples is
recommended. FOBT with the single stool sample
collected on the clinician's fingertip during a DRE in
the health care setting is not recommended. Guaiac-based toilet bowl FOBT tests also 
are not
recommended. In comparison with guaiac-based
tests for the detection of occult blood,
immunochemical tests are more patient-friendly, and
are likely to be equal or better in sensitivity and
specificity. There is no justification for repeating
FOBT in response to an initial positive finding.
Stool DNA
test,b or
Interval uncertain, starting at age 50 y.
FSIG, or Every 5 y, starting at age 50 y. FSIG can be
performed alone, or consideration can be given to
combining FSIG performed every 5 y with a highly
sensitive guaiac-based FOBT or FIT performed
annually.
DCBE or Every 5 y, starting at age 50 y.
Colonoscopy Every 10 y, starting at age 50 y.
CT
colonography
Every 5 y, starting at age 50 y.





















At the time of menopause, women at average risk
should be informed about the risks and symptoms of
endometrial cancer and strongly encouraged to




aged 55–74 y in
good health with
at least a 30
pack-y history
LDCT Clinicians with access to high-volume, high-quality
lung cancer screening and treatment centers should
initiate a discussion about lung cancer screening with
apparently healthy patients aged 55–74 y who have
at least a 30 pack-y smoking history, and who
currently smoke or have quit within the past 15 y. A
process of informed and shared decision-making with
a clinician related to the potential benefits, limitations,
and harms associated with screening for lung cancer
with LDCT should occur before any decision is made
to initiate lung cancer screening. Smoking cessation
counseling remains a high priority for clinical
attention in discussions with current smokers, who
should be informed of their continuing risk of lung
cancer. Screening should not be viewed as an
alternative to smoking cessation.
Prostate Men, aged ≥50 y DRE and PSA Men who have at least a 10-y life expectancy should
have an opportunity to make an informed decision
with their health care provider about whether to be
screened for prostate cancer, after receiving
information about the potential benefits, risks, and
uncertainties associated with prostate cancer
screening. Prostate cancer screening should not







On the occasion of a periodic health examination, the
cancer-related checkup should include examination
for cancers of the thyroid, testicles, ovaries, lymph
nodes, oral cavity, and skin, as well as health
counseling about tobacco, sun exposure, diet and
nutrition, risk factors, sexual practices, and
environmental and occupational exposures.
ACS indicates American Cancer Society; BSE, breast self-examination; CBE, clinical breast examination; Pap, Papanicolaou; HPV, human 
papillomavirus; FOBT, fecal occult blood test; FIT, fecal immunochemical test; DRE, digital rectal examination; FSIG, flexible sigmoidoscopy; 
DCBE, double-contrast barium enema; CT, computed tomography; LDCT, low-dose helical CT; PSA, prostate-specific antigen.
a
Beginning at age 40 y, annual CBE should ideally be performed prior to mammography.
b
The stool DNA test approved for colorectal cancer screening in 2008 is no longer commercially available. New stool DNA tests are presently 
undergoing evaluation and may become available at some future time.
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Table 3
Summary of Potential Long-term and Late Effects of Colorectal Cancer and Its Treatment.
Treatment Type Long-Term Effects Late Effects
Surgery • Ostomy care and complications
• Urogenital / sexual dysfunction – e.g., erectile 
dysfunction, dyspareunia, vaginal dryness, 
incontinence
• Frequent and / or urgent bowel movements or loose 
bowels
• Gas and / or bloating
• Incisional hernia
• Increased risk of bowel obstruction
Pelvic Radiation • Urogenital dysfunction / sexual dysfunction – e.g., 




• Rectal ulceration and / or bleeding
• Rectal emptying problems / incontinence
• Frequent bowel movements
• Abdominal pain
• Localized skin changes
• Infertility
• Bowel obstruction
• Bone fracture in sacral region
• Second primary cancers in the 
radiation field
Chemotherapy • Peripheral chronic neuropathy
• Cognitive function deficits – e.g., confusion, 
lethargy
• Chronic fatigue
• Dental / oral complications
General Psychosocial Long-term and Late Effects
• Depression
• Distress – multi-factorial unpleasant experience of psychological, social, and/or spiritual nature
• Worry, anxiety
• Fear of recurrence
• Fear of pain
• End of life concerns: death and dying
• Loss of sexual function and/or desire
• Challenges with body image (secondary to surgery, hormonal therapy)
• Challenges with self-image
• Relationship and other social role difficulties
• Return to work concerns and financial challenges
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Table 4
Guidelines for the Assessment and Management of Physical and Psychosocial Long-Term and Late Effects
Guideline Level of Evidencea
Bowel/Gastrointestinal Issues
• Discuss frequency and/or urgency of bowel movements or loose bowels
• Assess for rectal ulceration and/or bleeding
• Assess for rectal emptying problems/incontinence
• Discuss bowel function and symptoms (e.g., rectal bleeding) with survivors.
• Refer survivors with persistent rectal symptoms (e.g., bleeding, sphincter dysfunction, rectal urgency 
and frequency) to the appropriate specialist.
III
Cognitive Function
• Screen for problems such as depression and anxiety that might worsen cognition and refer for treatment
• Refer patients with a positive screen for formal Neurocognitive training.
0
Dental/Oral
• Monitor for loss of taste and dry mouth
• Recommend saliva substitutes or medications to provide symptom relief
• Recommend attention to good oral hygiene (flossing, brushing with fluoride toothpaste, regular dental 
care)
0
Distress / Depression / Anxiety
• Level of risk: Higher for those with a stoma and those with sexual dysfunction
• Screen for distress / depression / anxiety periodically (at least annually) using a simple screening tool, 
such as the Distress Thermometer.
• Manage distress / depression using in-office counseling resources, pharmacotherapy, or prescribe 
exercise as appropriate.
• If office-based counseling and treatment are insufficient, refer survivors experiencing distress / 
depression for further evaluation and or treatment by appropriate specialists.
I
Fatigue
• Assess with a validated instrument such as the MDASI, BFI, FACT G-7 or FACT-C
• Recommend psychosocial support interventions and/or mind-body interventions
• Recommend 150 minutes of physical activity per week plus strength training per ACS Nutrition & 
Physical Activity Guidelines for Cancer Survivors
• Recommend optimizing nutrition per ACS Nutrition & Physical Activity Guidelines for Cancer 
Survivors
• For chronic fatigue, refer to rehabilitation
I
Neuropathy
• Focus on prevention; strong evidence for therapy is lacking
• Assess with Total Neuropathy Score (TNSc) or other validated tool for patients receiving oxaliplatin
• Higher risk criteria
◦ Patients who receive a cumulative dose of >900mg/m2 are at higher risk
◦ Patients with pre-existing neuropathy, alcoholism and diabetes mellitus
• Treat with duloxetine (moderate recommendation)
0
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Guideline Level of Evidencea
• No evidence to support tricyclic antidepressants, gabapentin or topical gel containing baclofen, 
amitriptyline HCL, and ketamine, but these therapies have been used for other neuropathic pain 
conditions
• Refer to rehabilitation and pain management as needed
Ostomy/Stoma Issues
• Rectal cancer survivors are more likely to need a permanent stoma than colon cancer survivors
• Monitor and manage sexual dysfunction as needed




• Assess for incisional hernia with complications
• Consider opioid analgesics, utilization of pain management services, if available, and incorporation of 
behavioral interventions/physical activity and/or rehabilitation/physical therapy have demonstrated 
efficacy in pain control in systematic reviews in other cancers or pain syndromes
I
Sexual Functioning/Fertility
• Level of risk: Affects small percent of CRC survivors
• Higher risk criterion: women who receive pelvic radiotherapy
• Discuss urogenital dysfunction/sexual dysfunction (e.g., erectile dysfunction, dyspareunia, vaginal 
dryness, incontinence)
• Men who receive pelvic radiotherapy or oxaliplatin may be at higher risk for gonadotoxicity (limited 
evidence)
◦ Evaluate for Leydig cell dysfunction
◦ Initiate testosterone replacement as indicated
• Women survivors of rectal cancer with a stoma are at higher risk for vaginal dryness and dyspareunia
◦ Recommend vaginal moisturizers and water or silicone-based lubricants during intercourse
• For men with erectile dysfunction, treat with oral phosphodiesterase-5 inhibitors











• Assess for stress, urge and overflow urinary incontinence in patients who received surgery
• Recommend Kegel exercises for stress incontinence unless denervation occurred during surgery
• Recommend anticholinergic drugs for stress incontinence
• Recommend antimuscarinic drugs for urge or mixed incontinence
• Patients with hypocontractile bladders may require catherization
• Refer patients with prolonged urinary retention post operatively to urologist
Radiation
• Assess for incontinence, frequency, urgency, dysuria or hematuria in patients who received surgery
• Recommend limiting caffeine and fluid intake and avoiding foods that irritate the bladder such as citrus 
and tomatoes for irritative symptoms




Level of evidence: I, meta analyses of randomized controlled trials (RCTs); IA, RCT of colorectal cancer survivors; IB, RCT based on cancer 
survivors across multiple sites; IC, RCT not based on cancer survivors, but on general population experiencing a specific long-term or late effect 
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(e.g., chronic diarrhea, sexual dysfunction, etc.); IIA, non-RCT based on colorectal cancer survivors; IIB, non-RCT based on cancer survivors 
across multiple sites; IIC, non-RCT not based on cancer survivors but on general population experiencing a specific long-term or late effect (e.g., 
chronic diarrhea, sexual dysfunction, etc.); III, case study; 0, expert opinion, observation, clinical practice, literature review, or pilot study.
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Table 5
Health Promotion Guidelines
Guideline Level of Evidencea
Counsel survivors to achieve and maintain a healthy weight.
• If overweight or obese, limit consumption of high-calorie foods and beverages and increase physical 
activity to promote weight loss.
• Weight management is considered a priority standard of care.
0, III
Counsel survivors to engage in regular physical activity.
• Avoid inactivity and return to normal daily activities as soon as possible following diagnosis.
• Aim to exercise at least 150 minutes per week.
• Include strength training exercises at least 2 days per week.
• Physical activity significantly improves quality of life, physical functioning, peak oxygen consumption 
and reduces symptoms of fatigue.
0, IB
Counsel survivors to achieve a dietary pattern that is high in vegetables, fruits, and whole grains.
• Diets should emphasize vegetables and fruits, have low amounts of saturated fats, and include sufficient 
dietary fiber.
• Follow the American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Survivors.
0
Counsel survivors to avoid tobacco products or offer cessation counseling and/or
refer survivors to cessation counseling and resources.
0, III
Counsel survivors to avoid or limit alcohol consumption.
• Women should limit their alcohol consumption to no more than one drink per day; men should limit their 
alcohol consumption to no more than two drinks per day.
0
Refer survivors with chronic bowel problems or surgery that affects normal
nutrient absorption to a registered dietitian to modify their diets to accommodate
these changes and maintain optimal health.
0
a
Level of evidence: I, meta analyses of randomized controlled trials (RCTs); IA, RCT of colorectal cancer survivors; IB, RCT based on cancer 
survivors across multiple sites; IC, RCT not based on cancer survivors, but on general population experiencing a specific long-term or late effect 
(e.g., chronic diarrhea, sexual dysfunction, etc.); IIA, non-RCT based on colorectal cancer survivors; IIB, non-RCT based on cancer survivors 
across multiple sites; IIC, non-RCT not based on cancer survivors but on general population experiencing a specific long-term or late effect (e.g., 
chronic diarrhea, sexual dysfunction, etc.); III, case study; 0, expert opinion, observation, clinical practice, literature review, or pilot study
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Table 6
Care Coordination Guidelines
Guideline Level of Evidencea
• Consult with cancer treatment team and request a treatment summary and survivorship care plan. 0, III
• Coordinate care with other medical specialists to address physical effects (e.g., cardiovascular issues, 
rheumatologic problems).
0, IA
• Refer survivors to behavioral specialist to address psychosocial issues (e.g., cognitive dysfunction, 
depression, fear of recurrence, body image and sexual dysfunction).
I
• Refer survivors to rehabilitative specialists to address issues (e.g., lingering fatigue). 0
• Primary care clinician follow-up should:
◦ Check for early local or regional cancer recurrence.
◦ Detect recurrence or 2nd primary cancers early.
◦ Treat ongoing and detect any new physical and psychosocial untoward effects from past colorectal 
cancer treatment.
◦ Periodically update the survivor’s family history; new colorectal cancers or FAP in the family might 
make the survivor a candidate for cancer genetic testing.
0, I
FAP indicates familial adenomatous polyposis.
a
Level of evidence: I, meta analyses of randomized controlled trials (RCTs); IA, RCT of colorectal cancer survivors; IB, RCT based on cancer 
survivors across multiple sites; IC, RCT not based on cancer survivors, but on general population experiencing a specific long-term or late effect 
(e.g., chronic diarrhea, sexual dysfunction, etc.); IIA, non-RCT based on colorectal cancer survivors; IIB, non-RCT based on cancer survivors 
across multiple sites; IIC, non-RCT not based on cancer survivors but on general population experiencing a specific long-term or late effect (e.g., 
chronic diarrhea, sexual dysfunction, etc.); III, case study; 0, expert opinion, observation, clinical practice, literature review, or pilot study
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